254 related articles for article (PubMed ID: 23881917)
1. Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.
Koss B; Morrison J; Perciavalle RM; Singh H; Rehg JE; Williams RT; Opferman JT
Blood; 2013 Aug; 122(9):1587-98. PubMed ID: 23881917
[TBL] [Abstract][Full Text] [Related]
2. Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL
Budhraja A; Turnis ME; Churchman ML; Kothari A; Yang X; Xu H; Kaminska E; Panetta JC; Finkelstein D; Mullighan CG; Opferman JT
Clin Cancer Res; 2017 Dec; 23(24):7558-7568. PubMed ID: 28974549
[No Abstract] [Full Text] [Related]
3. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
4. Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of
Yang L; Qiu Q; Tang M; Wang F; Yi Y; Yi D; Yang Z; Zhu Z; Zheng S; Yang J; Pei H; Zheng L; Chen Y; Gou L; Luo L; Deng X; Ye H; Hu Y; Niu T; Chen L
Clin Cancer Res; 2019 Dec; 25(24):7527-7539. PubMed ID: 31439580
[TBL] [Abstract][Full Text] [Related]
5. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: a novel transgenic model for human Ph1-positive leukemias.
Honda H; Oda H; Suzuki T; Takahashi T; Witte ON; Ozawa K; Ishikawa T; Yazaki Y; Hirai H
Blood; 1998 Mar; 91(6):2067-75. PubMed ID: 9490692
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Boulos N; Mulder HL; Calabrese CR; Morrison JB; Rehg JE; Relling MV; Sherr CJ; Williams RT
Blood; 2011 Mar; 117(13):3585-95. PubMed ID: 21263154
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
Okabe S; Tauchi T; Ohyashiki K
Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
[TBL] [Abstract][Full Text] [Related]
8. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
9. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.
Uchida N; Hanawa H; Dan K; Inokuchi K; Shimada T
J Nippon Med Sch; 2009 Jun; 76(3):134-47. PubMed ID: 19602820
[TBL] [Abstract][Full Text] [Related]
10. The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.
Rafiei A; Mian AA; Döring C; Metodieva A; Oancea C; Thalheimer FB; Hansmann ML; Ottmann OG; Ruthardt M
PLoS Genet; 2015 Apr; 11(4):e1005144. PubMed ID: 25919613
[TBL] [Abstract][Full Text] [Related]
11. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Drexler HG; MacLeod RA; Uphoff CC
Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
[TBL] [Abstract][Full Text] [Related]
12. BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.
Voncken JW; Kaartinen V; Pattengale PK; Germeraad WT; Groffen J; Heisterkamp N
Blood; 1995 Dec; 86(12):4603-11. PubMed ID: 8541551
[TBL] [Abstract][Full Text] [Related]
13. Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Doki N; Kitaura J; Uchida T; Inoue D; Kagiyama Y; Togami K; Isobe M; Ito S; Maehara A; Izawa K; Kato N; Oki T; Harada Y; Nakahara F; Harada H; Kitamura T
Int J Hematol; 2012 Feb; 95(2):167-75. PubMed ID: 22189847
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
15. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
[TBL] [Abstract][Full Text] [Related]
16. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
17. Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia.
Chen Z; Shojaee S; Buchner M; Geng H; Lee JW; Klemm L; Titz B; Graeber TG; Park E; Tan YX; Satterthwaite A; Paietta E; Hunger SP; Willman CL; Melnick A; Loh ML; Jung JU; Coligan JE; Bolland S; Mak TW; Limnander A; Jumaa H; Reth M; Weiss A; Lowell CA; Müschen M
Nature; 2015 May; 521(7552):357-61. PubMed ID: 25799995
[TBL] [Abstract][Full Text] [Related]
18. A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
Mishra S; Zhang B; Groffen J; Heisterkamp N
Leukemia; 2004 Jan; 18(1):23-8. PubMed ID: 14603339
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
20. The Bcr N-terminal oligomerization domain contributes to the full oncogenicity of P190 Bcr/Abl in transgenic mice.
Heisterkamp N; Voncken JW; Senadheera D; Hemmeryckx B; Gonzalez-Gomez I; Reichert A; Pattengale PK; Groffen J
Int J Mol Med; 2001 Apr; 7(4):351-7. PubMed ID: 11254872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
